DRUG · Mapped RxNorm record
neratinib
Normalized identity: neratinibView linked drug · Find medicine records ·
Find other trials using this name
Clinical trial
Neratinib With and Without Temsirolimus for Patients With HER2 Activating Mutations in Non-Small Cell Lung Cancer
NCT01827267
Drugs and interventions used in this trial
2 registeredThese interventions are listed by ClinicalTrials.gov. An RxNorm link indicates a mapped medicine record; the registry name alone is not proof of a specific branded formulation.
DRUG · Mapped RxNorm record
temsirolimus
Normalized identity: temsirolimusView linked drug · Find medicine records ·
Find other trials using this name
No matching interventions in this trial.
Study at a glance
Registry-backedNeratinib With and Without Temsirolimus for Patients With HER2 Activating Mutations in Non-Small Cell Lung Cancer
Design: INTERVENTIONAL · Status: COMPLETED · Phase: PHASE2
Read study objectives, eligibility and outcome measures at ClinicalTrials.govAdvertisement
Conditions
HER2-mutant Non-Small Cell Lung Cancerunresolved
Interventions
neratinibDRUG · verified · RxNorm: neratinib
temsirolimusDRUG · verified · RxNorm: temsirolimus
Sponsors & collaborators
Puma Biotechnology, Inc.lead sponsor
Mapped research locations
BostonMassachusetts, United States3New YorkNew York, United States1HoustonTexas, United States1DallasTexas, United States1BaltimoreMaryland, United States1St LouisMissouri, United States1NashvilleTennessee, United States1PittsburghPennsylvania, United States1ColumbusOhio, United States1TampaFlorida, United States1AuroraColorado, United States1ToulouseFrance1
Registry source
Open the source record to verify current eligibility, contacts, locations and registry updates.
Open NCT01827267 on ClinicalTrials.gov ↗Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.